(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 June 2022 (09.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/120094 A3

(51) International Patent Classification:
A61K 48/00 (2006.01) *A61P 7/00* (2006.01)
A61K 31/395 (2006.01)

(21) International Application Number:
PCT/US2021/061672

(22) International Filing Date:
02 December 2021 (02.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/120,885 03 December 2020 (03.12.2020) US

(71) Applicant: **SCRIBE THERAPEUTICS INC.** [US/US]; 1150 Marina Village Parkway, Alameda, California 94501 (US).

(72) Inventors: **OAKES, Benjamin**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **HIGGINS, Sean**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DENNY, Sarah**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **STAAHL, Brett T.**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **COLIN, Isabel**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **ADIL, Maroof**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **URNES, Cole**; c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

(74) Agent: **ROY, Madhuri** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A




FIG. 1

(57) Abstract: Provided herein are systems comprising Class 2, Type V CRISPR polypeptides, guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a BCL11A gene. The systems are also useful for the modification of cells in subjects with a hemoglobinopathy-related disease. Also provided are methods of treatment of subjects having a hemoglobinopathy-related disease by administration of the systems or nucleic acids encoding such systems that target the BCL11A gene in such subjects.

WO 2022/120094 A3

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
25 August 2022 (25.08.2022)